Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway

Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway

Abstract Background Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide, which is partially due to limited progress of therapy. Apatinib, an inhibitor of VEGFR2, has a promising antitumor effect on malignancies. However, the underlying mechanism of its antitumor effect...

Full description

Bibliographic Details
Main Authors: Bin Wei, Yuanyuan Wang, Jiawei Wang, Xiaomin Cai, Lingyan Xu, Jingjing Wu, Ying Wang, Wen Liu, Yanhong Gu, Wenjie Guo, Qiang Xu
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Cancer Cell International
Subjects:
Apatinib
Esophageal cancer
Tumor progression
Cisplatin sensitivity
VEGFR2
Akt/β-catenin pathway
Online Access:http://link.springer.com/article/10.1186/s12935-020-01290-z

Internet

http://link.springer.com/article/10.1186/s12935-020-01290-z

Similar Items